Shunsuke Miyamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shunsuke Miyamoto has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Hiroyuki Kitano
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
15 shared publications - Kohei Kobatake
Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
15 shared publications - Nobuyuki Hinata
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
15 shared publications - Yohei Sekino
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
15 shared publications Keisuke Hieda
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
12 shared publications- Miki Naito
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
12 shared publications
Latest Publications
- Open Access
- 8 August 2026
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1)
Impact of surgical start time on clinical outcomes in urologic surgery: a single-center study of major oncologic surgeries and adrenalectomy
- 8 August 2026
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1)
Open AccessImpact of surgical start time on clinical outcomes in urologic surgery: a single-center study of major oncologic surgeries and adrenalectomy
- Open Access
- 23 July 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (7) , e70579
External Validation of Prognostic Models for Nonmetastatic Clear Cell Renal Cell Carcinoma in a Japanese Cohort: Evaluation of Predictive Performance
Objectives: To characterize contemporary postoperative outcomes and risk stratification in a large Japanese real‐world cohort of patients with clinically nonmetastatic clear cell renal cell carcinoma (ccRCC), and to externally validate commonly used prognostic models. Methods: We retrospectively analyzed 1677 Japanese patients with clinically nonmetastatic ccRCC who underwent radical or partial nephrectomy between 2010 and 2025. Disease‐free survival (DFS) and overall survival (OS) were evaluated. The Leibovich score, SSIGN score, AUA risk groups, and GRANT score were externally validated. Model discrimination was assessed using Harrell's C‐index. Results: During a median follow‐up of 36 months, 160 patients (9.5%) experienced recurrence and 115 (6.9%) died, including 28 renal cancer‐specific deaths. The 3‐, 5‐, and 10‐year DFS rates were 91.2%, 87.6%, and 75.9%, respectively; corresponding OS rates were 95.0%, 91.1%, and 80.9%. Pathological T stage, WHO/ISUP grade, and lymphovascular invasion (LVI) were independently associated with DFS, whereas age, ASA physical status, and LVI were independently associated with OS. All four models significantly stratified DFS and OS. For DFS, the Leibovich score showed favorable discrimination, with a C‐index of 0.785 as a continuous score and 0.769 as a risk‐group model. In a post hoc exploratory analysis, adding LVI to the Leibovich score slightly increased the C‐index for DFS, but the improvement was not statistically significant. Conclusions: Established prognostic models consistently stratified recurrence risk in Japanese patients with clinically nonmetastatic ccRCC. The Leibovich score may serve as a useful reference for postoperative risk assessment, whereas the added value of LVI requires further validation.
- 23 July 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (7) , e70579
Open AccessExternal Validation of Prognostic Models for Nonmetastatic Clear Cell Renal Cell Carcinoma in a Japanese Cohort: Evaluation of Predictive Performance
Objectives: To characterize contemporary postoperative outcomes and risk stratification in a large Japanese real‐world cohort of patients with clinically nonmetastatic clear cell renal cell carcinoma (ccRCC), and to externally validate commonly used prognostic models. Methods: We retrospectively analyzed 1677 Japanese patients with clinically nonmetastatic ccRCC who underwent radical or partial nephrectomy between 2010 and 2025. Disease‐free survival (DFS) and overall survival (OS) were evaluated. The Leibovich score, SSIGN score, AUA risk groups, and GRANT score were externally validated. Model discrimination was assessed using Harrell's C‐index. Results: During a median follow‐up of 36 months, 160 patients (9.5%) experienced recurrence and 115 (6.9%) died, including 28 renal cancer‐specific deaths. The 3‐, 5‐, and 10‐year DFS rates were 91.2%, 87.6%, and 75.9%, respectively; corresponding OS rates were 95.0%, 91.1%, and 80.9%. Pathological T stage, WHO/ISUP grade, and lymphovascular invasion (LVI) were independently associated with DFS, whereas age, ASA physical status, and LVI were independently associated with OS. All four models significantly stratified DFS and OS. For DFS, the Leibovich score showed favorable discrimination, with a C‐index of 0.785 as a continuous score and 0.769 as a risk‐group model. In a post hoc exploratory analysis, adding LVI to the Leibovich score slightly increased the C‐index for DFS, but the improvement was not statistically significant. Conclusions: Established prognostic models consistently stratified recurrence risk in Japanese patients with clinically nonmetastatic ccRCC. The Leibovich score may serve as a useful reference for postoperative risk assessment, whereas the added value of LVI requires further validation.
- Open Access
- 30 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Clinical and genomic characteristics of primary resistant disease to first-line immuno-oncology plus VEGFR inhibitor therapy in metastatic renal cell carcinoma
Primary resistant disease (PRD) to immuno-oncology plus vascular endothelial growth factor receptor inhibitor (IOVE) therapy is a critical unmet need in metastatic renal cell carcinoma (mRCC), yet its clinical and molecular features remain poorly defined. We provide the first integrated clinical and genomic characterization of PRD, combining two complementary, non-overlapping cohorts: a real-world clinical cohort of 159 patients (Hiroshima Cancer Registry Project, H-CARP) and a national genomic database (Center for Cancer Genomics and Advanced Therapeutics, C-CAT). PRD (n = 20 [12.6%]) defined a distinct high-risk group with markedly shorter progression-free survival, PFS2, and overall survival (OS) and a median OS of 8.5 months. Notably, liver metastasis was a strong, readily available independent predictor of PRD (odds ratio 4.99; p = 0.011), enabling early risk stratification, and non-clear cell histology was enriched among PRD. The comparable OS with or without subsequent therapy underscores an urgent need for novel strategies. Exploratory genomic profiling revealed candidate, hypothesis-generating correlates of resistance (lower VHL and PBRM1; higher TSC2 and MSH3 alterations). By linking real-world outcomes with national genomic data, this study establishes a foundation for early identification and biomarker-guided management of PRD.
- 30 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessClinical and genomic characteristics of primary resistant disease to first-line immuno-oncology plus VEGFR inhibitor therapy in metastatic renal cell carcinoma
Primary resistant disease (PRD) to immuno-oncology plus vascular endothelial growth factor receptor inhibitor (IOVE) therapy is a critical unmet need in metastatic renal cell carcinoma (mRCC), yet its clinical and molecular features remain poorly defined. We provide the first integrated clinical and genomic characterization of PRD, combining two complementary, non-overlapping cohorts: a real-world clinical cohort of 159 patients (Hiroshima Cancer Registry Project, H-CARP) and a national genomic database (Center for Cancer Genomics and Advanced Therapeutics, C-CAT). PRD (n = 20 [12.6%]) defined a distinct high-risk group with markedly shorter progression-free survival, PFS2, and overall survival (OS) and a median OS of 8.5 months. Notably, liver metastasis was a strong, readily available independent predictor of PRD (odds ratio 4.99; p = 0.011), enabling early risk stratification, and non-clear cell histology was enriched among PRD. The comparable OS with or without subsequent therapy underscores an urgent need for novel strategies. Exploratory genomic profiling revealed candidate, hypothesis-generating correlates of resistance (lower VHL and PBRM1; higher TSC2 and MSH3 alterations). By linking real-world outcomes with national genomic data, this study establishes a foundation for early identification and biomarker-guided management of PRD.
- Open Access
- 8 June 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (6) , e70538
Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/ DD ) and Pure Urothelial Carcinoma Using a Large‐Scale Japanese Genomic Panel Dataset
Objectives: Urothelial carcinoma (UC) is a common malignancy; however, UC subtypes/divergent differentiation (S/DD) accounts for only 10%–20% of overall cases. S/DD's aggressive biological behavior significantly affects its prognosis and therapeutic decision‐making; thus, elucidating its genomic landscape within UC is important. This retrospective observational study aimed to evaluate and compare the molecular characteristics of S/DD and pure urothelial carcinoma (PUC). Methods: Comprehensive cancer genomic profiling data were obtained from the Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) and the MSK2022 dataset. The association between S/DD and clinicopathological features was evaluated in an independent Hiroshima University cohort. Results: Across both C‐CAT and MSK2022 datasets, TP53 and RB1 mutations were more prevalent in S/DD, whereas KDM6A , ARID1A , and FGFR3 mutations were more common in PUC. High‐frequency copy number alterations included MYC and RB1 in S/DD, and CDKN2A , CDKN2B , CCND1 , FGF19 , FGF4 , and FGF3 in PUC. In the Hiroshima University cohort, S/DD was associated with adverse clinicopathological features and a poor prognosis. Immunohistochemistry demonstrated a positive correlation of S/DD with PD‐L1, EGFR, and p53 expression in upper tract UC tissues, and an inverse correlation with FGFR3, GATA3, Nectin4, and TROP2 expression. Conclusions: Using a large‐scale Japanese genomic panel dataset, we characterized the molecular alterations associated with S/DD. S/DD frequently exhibits low Nectin‐4 expression and basal‐like molecular features, which may have implications for treatment selection and inform future therapeutic strategies.
- 8 June 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (6) , e70538
Open AccessComprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/ DD ) and Pure Urothelial Carcinoma Using a Large‐Scale Japanese Genomic Panel Dataset
Objectives: Urothelial carcinoma (UC) is a common malignancy; however, UC subtypes/divergent differentiation (S/DD) accounts for only 10%–20% of overall cases. S/DD's aggressive biological behavior significantly affects its prognosis and therapeutic decision‐making; thus, elucidating its genomic landscape within UC is important. This retrospective observational study aimed to evaluate and compare the molecular characteristics of S/DD and pure urothelial carcinoma (PUC). Methods: Comprehensive cancer genomic profiling data were obtained from the Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) and the MSK2022 dataset. The association between S/DD and clinicopathological features was evaluated in an independent Hiroshima University cohort. Results: Across both C‐CAT and MSK2022 datasets, TP53 and RB1 mutations were more prevalent in S/DD, whereas KDM6A , ARID1A , and FGFR3 mutations were more common in PUC. High‐frequency copy number alterations included MYC and RB1 in S/DD, and CDKN2A , CDKN2B , CCND1 , FGF19 , FGF4 , and FGF3 in PUC. In the Hiroshima University cohort, S/DD was associated with adverse clinicopathological features and a poor prognosis. Immunohistochemistry demonstrated a positive correlation of S/DD with PD‐L1, EGFR, and p53 expression in upper tract UC tissues, and an inverse correlation with FGFR3, GATA3, Nectin4, and TROP2 expression. Conclusions: Using a large‐scale Japanese genomic panel dataset, we characterized the molecular alterations associated with S/DD. S/DD frequently exhibits low Nectin‐4 expression and basal‐like molecular features, which may have implications for treatment selection and inform future therapeutic strategies.
- Open Access
Bone Marrow-Derived Mesenchymal Stem Cells Differentiate into Cancer-Associated Fibroblasts and Promote Tumor Growth in Renal Cell Carcinoma
Background: Tumor–stroma interactions play a critical role in renal cell carcinoma (RCC) progression. Cancer-associated fibroblasts (CAFs) are considered key components of the tumor microenvironment; however, their origin remains controversial. This study aimed to determine whether bone marrow-derived mesenchymal stem cells (MSCs) contribute to CAF-like stromal changes and RCC progression. Methods: An orthotopic xenograft mouse model was established using luciferase- and GFP-labeled Caki-1 cells. MSCs labeled with PKH26 were administered intravenously. Tumor growth was evaluated using an in vivo imaging system and tumor volume measurements. Immunohistochemical analyses were performed to assess MSC localization and α-smooth muscle actin (α-SMA) expression. In vitro proliferation and migration assays were conducted using direct and indirect co-culture systems. Results: The intravenous administration of MSCs significantly increased tumor growth and bioluminescence intensity in an orthotopic model. The tumor volumes were significantly larger in the MSC-treated versus control group. An immunofluorescence analysis demonstrated partial co-localization of PKH26-labeled MSCs with α-SMA-positive fibroblast-like cells, suggesting acquisition of CAF-like features. Direct co-culture with MSCs significantly enhanced RCC cell proliferation and migration in vitro, whereas culturing in conditioned medium alone did not produce similar effects. Conclusions: Exogenously administered bone marrow-derived MSCs may be recruited into RCC tissues and acquire CAF-like features through interactions with tumor cells. These findings suggest that stromal–tumor cell interactions within the tumor microenvironment may contribute to RCC progression and represent a potential therapeutic target.
Open AccessBone Marrow-Derived Mesenchymal Stem Cells Differentiate into Cancer-Associated Fibroblasts and Promote Tumor Growth in Renal Cell Carcinoma
Background: Tumor–stroma interactions play a critical role in renal cell carcinoma (RCC) progression. Cancer-associated fibroblasts (CAFs) are considered key components of the tumor microenvironment; however, their origin remains controversial. This study aimed to determine whether bone marrow-derived mesenchymal stem cells (MSCs) contribute to CAF-like stromal changes and RCC progression. Methods: An orthotopic xenograft mouse model was established using luciferase- and GFP-labeled Caki-1 cells. MSCs labeled with PKH26 were administered intravenously. Tumor growth was evaluated using an in vivo imaging system and tumor volume measurements. Immunohistochemical analyses were performed to assess MSC localization and α-smooth muscle actin (α-SMA) expression. In vitro proliferation and migration assays were conducted using direct and indirect co-culture systems. Results: The intravenous administration of MSCs significantly increased tumor growth and bioluminescence intensity in an orthotopic model. The tumor volumes were significantly larger in the MSC-treated versus control group. An immunofluorescence analysis demonstrated partial co-localization of PKH26-labeled MSCs with α-SMA-positive fibroblast-like cells, suggesting acquisition of CAF-like features. Direct co-culture with MSCs significantly enhanced RCC cell proliferation and migration in vitro, whereas culturing in conditioned medium alone did not produce similar effects. Conclusions: Exogenously administered bone marrow-derived MSCs may be recruited into RCC tissues and acquire CAF-like features through interactions with tumor cells. These findings suggest that stromal–tumor cell interactions within the tumor microenvironment may contribute to RCC progression and represent a potential therapeutic target.
- Open Access
- 30 April 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (5) , 102568
Comprehensive Analysis of Tumor Mutational Burden in Prostate Cancer: Multipublic Dataset Analysis
- 30 April 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (5) , 102568
Open AccessComprehensive Analysis of Tumor Mutational Burden in Prostate Cancer: Multipublic Dataset Analysis
- Open Access
- 22 April 2026
- Published by Wiley in The Prostate
- Vol. 86 (9) , 1053-1060
Impact of the Nadir Androgen Receptor Signaling Inhibitor‐Derived Integrative Response Model in Real‐World Patients With Metastatic Castration‐Sensitive Prostate Cancer
Background: Early deep prostate‐specific antigen (PSA) decline after the initiation of androgen receptor signaling inhibitor (ARSI) therapy is associated with favorable long‐term outcomes in metastatic castration‐sensitive prostate cancer (mCSPC). The Nadir ARSI‐Derived Integrative Response (NADIR) model was recently developed using Phase III trial data to predict the probability of achieving a favorable early PSA response. However, its performance in real‐world clinical settings remains unclear. Methods: We retrospectively reviewed 196 patients with mCSPC who received first‐line ARSI therapy at Hiroshima University Hospital and affiliated institutions between 2018 and 2025; 186 had complete data required to calculate the NADIR score. An early favorable PSA response was defined as a decline in PSA to ≤ 0.2 ng/mL within 6 months of treatment initiation. Model discrimination was assessed using the area under the receiver operating characteristic curve (AUC), and calibration was evaluated using calibration plots. Patients were stratified into tertiles based on the NADIR score, and time‐to‐event outcomes, including overall survival (OS) and time to castration‐resistant prostate cancer (CRPC), were analyzed using the Kaplan–Meier method. Results: The proportion of patients with an early favorable PSA response decreased stepwise across the upper, middle, and lower tertiles (61.3%, 33.8%, and 17.7%, respectively; Cochran–Armitage trend test, p < 0.01). The NADIR model demonstrated acceptable discrimination for predicting an early favorable PSA response, with an AUC of 0.74 (95% confidence interval [CI] 0.66–0.81). Agreement between predicted probabilities and observed outcomes was maintained across NADIR‐defined risk groups. In a univariable analysis treating the NADIR score as a continuous variable, higher NADIR scores were strongly associated with an early favorable PSA response (odds ratio per 10% increase, 1.74; 95% CI 1.36–2.23; p < 0.001). CRPC‐free survival differed significantly across NADIR‐defined tertiles, whereas OS did not differ significantly. Conclusions: In this real‐world cohort, the NADIR model retained acceptable predictive performance, suggesting applicability in routine clinical practice and potential utility in individualized pretreatment clinical management.
- 22 April 2026
- Published by Wiley in The Prostate
- Vol. 86 (9) , 1053-1060
Open AccessImpact of the Nadir Androgen Receptor Signaling Inhibitor‐Derived Integrative Response Model in Real‐World Patients With Metastatic Castration‐Sensitive Prostate Cancer
Background: Early deep prostate‐specific antigen (PSA) decline after the initiation of androgen receptor signaling inhibitor (ARSI) therapy is associated with favorable long‐term outcomes in metastatic castration‐sensitive prostate cancer (mCSPC). The Nadir ARSI‐Derived Integrative Response (NADIR) model was recently developed using Phase III trial data to predict the probability of achieving a favorable early PSA response. However, its performance in real‐world clinical settings remains unclear. Methods: We retrospectively reviewed 196 patients with mCSPC who received first‐line ARSI therapy at Hiroshima University Hospital and affiliated institutions between 2018 and 2025; 186 had complete data required to calculate the NADIR score. An early favorable PSA response was defined as a decline in PSA to ≤ 0.2 ng/mL within 6 months of treatment initiation. Model discrimination was assessed using the area under the receiver operating characteristic curve (AUC), and calibration was evaluated using calibration plots. Patients were stratified into tertiles based on the NADIR score, and time‐to‐event outcomes, including overall survival (OS) and time to castration‐resistant prostate cancer (CRPC), were analyzed using the Kaplan–Meier method. Results: The proportion of patients with an early favorable PSA response decreased stepwise across the upper, middle, and lower tertiles (61.3%, 33.8%, and 17.7%, respectively; Cochran–Armitage trend test, p < 0.01). The NADIR model demonstrated acceptable discrimination for predicting an early favorable PSA response, with an AUC of 0.74 (95% confidence interval [CI] 0.66–0.81). Agreement between predicted probabilities and observed outcomes was maintained across NADIR‐defined risk groups. In a univariable analysis treating the NADIR score as a continuous variable, higher NADIR scores were strongly associated with an early favorable PSA response (odds ratio per 10% increase, 1.74; 95% CI 1.36–2.23; p < 0.001). CRPC‐free survival differed significantly across NADIR‐defined tertiles, whereas OS did not differ significantly. Conclusions: In this real‐world cohort, the NADIR model retained acceptable predictive performance, suggesting applicability in routine clinical practice and potential utility in individualized pretreatment clinical management.
- Open Access
- 26 February 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (3) , e71687
KIFC1 is Associated With Sarcomatoid Differentiation, Immune Response, and a Poor Prognosis in Clear Cell Renal Cell Carcinoma
Introduction: Centrosome clustering is a cancer‐specific adaptation that allows cells with centrosome amplification to evade mitotic catastrophe and has emerged as a potential therapeutic target. We analyzed the prognostic role of several molecules related to centrosome clustering and found that Kinesin Family Member C1 ( KIFC1 ) was strongly associated with a poor prognosis. KIFC1, a kinesin motor protein, plays a central role in centrosome clustering. However, its biological and clinical significance in clear cell renal cell carcinoma (ccRCC) remains poorly understood. Methods: We conducted a comprehensive analysis using several public datasets (TCGA KIRC, JAVELIN101, IMmotion151, and others) and a Hiroshima ccRCC cohort ( n = 110) to evaluate the expression of KIFC1 , clinicopathological associations, the prognosis, and treatment response. Gene Set Enrichment Analysis was performed to explore associated pathways. Results: Immunohistochemical and in silico analyses showed that high KIFC1 expression was significantly associated with high tumor grade, advanced TNM stage, and sarcomatoid differentiation. A multivariate analysis demonstrated that the high‐expression of KIFC1 was independently associated with poor overall survival. Gene Set Enrichment Analysis revealed enrichment of epithelial–mesenchymal transition and interferon gamma response pathways in KIFC1 ‐high tumors. The expression of KIFC1 was also correlated with TKI resistance, immune response, high clonal neoantigen load, and BAP1 mutation. Conclusion: KIFC1 serves as a multifunctional molecule linking epithelial–mesenchymal transition, immune modulation, and treatment resistance. It may be a promising prognostic biomarker and therapeutic target in ccRCC, warranting further functional and clinical investigation.
- 26 February 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (3) , e71687
Open AccessKIFC1 is Associated With Sarcomatoid Differentiation, Immune Response, and a Poor Prognosis in Clear Cell Renal Cell Carcinoma
Introduction: Centrosome clustering is a cancer‐specific adaptation that allows cells with centrosome amplification to evade mitotic catastrophe and has emerged as a potential therapeutic target. We analyzed the prognostic role of several molecules related to centrosome clustering and found that Kinesin Family Member C1 ( KIFC1 ) was strongly associated with a poor prognosis. KIFC1, a kinesin motor protein, plays a central role in centrosome clustering. However, its biological and clinical significance in clear cell renal cell carcinoma (ccRCC) remains poorly understood. Methods: We conducted a comprehensive analysis using several public datasets (TCGA KIRC, JAVELIN101, IMmotion151, and others) and a Hiroshima ccRCC cohort ( n = 110) to evaluate the expression of KIFC1 , clinicopathological associations, the prognosis, and treatment response. Gene Set Enrichment Analysis was performed to explore associated pathways. Results: Immunohistochemical and in silico analyses showed that high KIFC1 expression was significantly associated with high tumor grade, advanced TNM stage, and sarcomatoid differentiation. A multivariate analysis demonstrated that the high‐expression of KIFC1 was independently associated with poor overall survival. Gene Set Enrichment Analysis revealed enrichment of epithelial–mesenchymal transition and interferon gamma response pathways in KIFC1 ‐high tumors. The expression of KIFC1 was also correlated with TKI resistance, immune response, high clonal neoantigen load, and BAP1 mutation. Conclusion: KIFC1 serves as a multifunctional molecule linking epithelial–mesenchymal transition, immune modulation, and treatment resistance. It may be a promising prognostic biomarker and therapeutic target in ccRCC, warranting further functional and clinical investigation.
- Open Access
- 26 January 2026
- Published by Wiley in The Prostate
- Vol. 86 (6) , 689-696
Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis
Background: In prostate cancer (PCa), smoking history is associated with more aggressive clinicopathological features, reduced efficacy of androgen deprivation therapy, and poorer overall survival (OS). However, its impact on survival outcomes in patients receiving taxane chemotherapy, poly ADP‐ribose polymerase inhibitor (PARPi), or immune checkpoint inhibitor (ICI) therapy for PCa remains unclear. We compared the genetic profiles of smokers and non‐smokers with PCa in several public databases to explore the potential influence of smoking on treatment outcomes. Methods: We retrospectively collected data on smoking history, tumor characteristics, genomic information, treatment history, and survival outcomes from three public databases to investigate the role of smoking in PCa. Patients were categorized into smokers and non‐smokers, and associations between smoking history and clinicopathological features, genetic profiles, and treatment outcomes were analyzed. Independent risk factors for OS were evaluated using multivariate Cox proportional hazard regression models. Results: Smokers exhibited significantly higher Gleason score, clinical stage, tumor mutational burden, fraction genome altered, and microsatellite instability scores than non‐smokers. The survival analysis revealed that smokers had significantly poorer OS than non‐smokers in the overall, hormone therapy, and PARPi therapy cohorts. In contrast, no significant difference in OS was observed between the taxane chemotherapy and ICI therapy cohorts. Furthermore, multivariate Cox proportional hazard regression analysis identified smoking history as an independent risk factor for OS in the overall, hormone therapy, and PARPi therapy cohorts. Oncoplot analysis showed a significantly higher frequency of TP53 mutations and PTEN copy number alterations in smokers than in non‐smokers. Conclusions: Smoking history was significantly associated with aggressive clinicopathological features and a poor prognosis in patients with PCa. Our findings suggest that smokers with PCa may receive greater benefit from the early administration of taxane chemotherapy in comparison to other treatment regimens.
- 26 January 2026
- Published by Wiley in The Prostate
- Vol. 86 (6) , 689-696
Open AccessGenomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis
Background: In prostate cancer (PCa), smoking history is associated with more aggressive clinicopathological features, reduced efficacy of androgen deprivation therapy, and poorer overall survival (OS). However, its impact on survival outcomes in patients receiving taxane chemotherapy, poly ADP‐ribose polymerase inhibitor (PARPi), or immune checkpoint inhibitor (ICI) therapy for PCa remains unclear. We compared the genetic profiles of smokers and non‐smokers with PCa in several public databases to explore the potential influence of smoking on treatment outcomes. Methods: We retrospectively collected data on smoking history, tumor characteristics, genomic information, treatment history, and survival outcomes from three public databases to investigate the role of smoking in PCa. Patients were categorized into smokers and non‐smokers, and associations between smoking history and clinicopathological features, genetic profiles, and treatment outcomes were analyzed. Independent risk factors for OS were evaluated using multivariate Cox proportional hazard regression models. Results: Smokers exhibited significantly higher Gleason score, clinical stage, tumor mutational burden, fraction genome altered, and microsatellite instability scores than non‐smokers. The survival analysis revealed that smokers had significantly poorer OS than non‐smokers in the overall, hormone therapy, and PARPi therapy cohorts. In contrast, no significant difference in OS was observed between the taxane chemotherapy and ICI therapy cohorts. Furthermore, multivariate Cox proportional hazard regression analysis identified smoking history as an independent risk factor for OS in the overall, hormone therapy, and PARPi therapy cohorts. Oncoplot analysis showed a significantly higher frequency of TP53 mutations and PTEN copy number alterations in smokers than in non‐smokers. Conclusions: Smoking history was significantly associated with aggressive clinicopathological features and a poor prognosis in patients with PCa. Our findings suggest that smokers with PCa may receive greater benefit from the early administration of taxane chemotherapy in comparison to other treatment regimens.
- Open Access
- 5 January 2026
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (2) , 1726-1734
Intraoperative real-time display of 3D reconstruction models in robot-assisted partial nephrectomy
Objective: Robot-assisted partial nephrectomy (RAPN) is a widely used technique for treating renal tumors. However, accurate identification of tumor locations and precise surgical planning remain challenging, particularly in cases with complex anatomy or tumors in difficult-to-reach areas. This study evaluated the usefulness of intraoperative real-time 3D reconstruction models for RAPN. Methods: We analyzed the data of 57 patients who underwent RAPN using 3D reconstruction models (3D-R group) and 173 patients who underwent RAPN without these models (control group). The models were generated from the preoperative Computed tomography images and displayed on a monitor in the operating room to plan surgical approaches and guide tumor dissection. Propensity score matching was performed to compare the surgical outcomes between the two groups. Results: The use of real-time 3D reconstruction models significantly improved surgical outcomes in the propensity score-matched cohort. The ischemia time was shorter in the 3D-R RAPN group than in the control group (p = 0.019). Significantly fewer overall and major complications were observed in the 3D-R RAPN group (p = 0.023 and p = 0.041, respectively). Additionally, the 3D-R RAPN group achieved the trifecta status at a significantly higher rate than the control group (p = 0.005). Conclusions: 3D reconstruction models are valuable tools for guiding RAPN, leading to shorter warm ischemia times, fewer complications, and a higher trifecta achievement rate, thereby enhancing the overall quality of care of patients undergoing RAPN.
- 5 January 2026
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (2) , 1726-1734
Open AccessIntraoperative real-time display of 3D reconstruction models in robot-assisted partial nephrectomy
Objective: Robot-assisted partial nephrectomy (RAPN) is a widely used technique for treating renal tumors. However, accurate identification of tumor locations and precise surgical planning remain challenging, particularly in cases with complex anatomy or tumors in difficult-to-reach areas. This study evaluated the usefulness of intraoperative real-time 3D reconstruction models for RAPN. Methods: We analyzed the data of 57 patients who underwent RAPN using 3D reconstruction models (3D-R group) and 173 patients who underwent RAPN without these models (control group). The models were generated from the preoperative Computed tomography images and displayed on a monitor in the operating room to plan surgical approaches and guide tumor dissection. Propensity score matching was performed to compare the surgical outcomes between the two groups. Results: The use of real-time 3D reconstruction models significantly improved surgical outcomes in the propensity score-matched cohort. The ischemia time was shorter in the 3D-R RAPN group than in the control group (p = 0.019). Significantly fewer overall and major complications were observed in the 3D-R RAPN group (p = 0.023 and p = 0.041, respectively). Additionally, the 3D-R RAPN group achieved the trifecta status at a significantly higher rate than the control group (p = 0.005). Conclusions: 3D reconstruction models are valuable tools for guiding RAPN, leading to shorter warm ischemia times, fewer complications, and a higher trifecta achievement rate, thereby enhancing the overall quality of care of patients undergoing RAPN.